Previous Issue
Volume 17, September-2
 
 
nutrients-logo

Journal Browser

Journal Browser

Nutrients, Volume 17, Issue 19 (October-1 2025) – 2 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
1880 KB  
Article
Physiologically Based Pharmacokinetic Modelling of Serum 25-Hydroxyvitamin D Concentrations in Schoolchildren Receiving Weekly Oral Vitamin D3 Supplementation
by Nadda Muhamad, Neil Walker, Keren Middelkoop, Davaasambuu Ganmaa, Adrian R. Martineau and Tao You
Nutrients 2025, 17(19), 3028; https://doi.org/10.3390/nu17193028 (registering DOI) - 23 Sep 2025
Abstract
Background: Following vitamin D3 oral administration, attained serum concentrations of its metabolite 25-hydroxyvitamin D3 (25(OH)D3) are variable among children. Methods: We developed physiologically based pharmacokinetic (PBPK) modelling using annually measured serum 25(OH)D3 concentrations in 77 Cape Town schoolchildren [...] Read more.
Background: Following vitamin D3 oral administration, attained serum concentrations of its metabolite 25-hydroxyvitamin D3 (25(OH)D3) are variable among children. Methods: We developed physiologically based pharmacokinetic (PBPK) modelling using annually measured serum 25(OH)D3 concentrations in 77 Cape Town schoolchildren aged 6–11 years who received weekly oral doses of 10,000 IU vitamin D3 for 3 years during a clinical trial (Δ25(OH)D = 32.2 nmol/L, 95% CI: [−3.2, 65.8] nmol/L). Simulations were performed to test the model on 463 other participants in the same trial, and in a cohort of 1756 Mongolian schoolchildren aged 6–11 years who received weekly oral doses of 14,000 IU vitamin D3 for 3 years in another trial. Results: The best model attributed most of the variability in post-supplementation 25(OH)D3 concentrations to hepatic clearance and covariates including weight (ΔAIC = −21) and ZBMI (body mass index Z-score, ΔAIC = −34). For 463 other children from the Cape Town trial (Δ25(OH)D = 25.8 nmol/L, 95% CI: [8.3, 47.2] nmol/L), mean estimation error was 5.3 nmol/L, and 76.7% of observations were within the 95% prediction intervals. Our simulation supported the previous proposal that serum 25(OH)D3 should exceed 50 nmol/L among 97.5% of European children at 24.4 μg/day vitamin D3 dosing. At a higher weekly dose (14,000 IU), the Mongolian children demonstrated a higher average increase in serum 25(OH)D3 (40.6 [−2.9, 88.9] nmol/L) but were overestimated by the model. Conclusion: We developed the first PBPK model to successfully predict the long-term serum 25(OH)D3 increases in healthy schoolchildren in Cape Town who received orally administered vitamin D3 and exhibited higher relative increases than Mongolian children. Full article
(This article belongs to the Section Pediatric Nutrition)
Show Figures

Figure 1

16 pages, 2697 KB  
Article
Weizmannia coagulans JA845 Postbiotics Alleviate Atherosclerosis via TMAO-Related Gut Microbiota Regulation and JAK/STAT3 Pathway Inhibition
by Liying Ma, Nan Li, Zijian Zhao, Yujuan Zhao, Ge Yang, Lei Zhao and Shengyu Li
Nutrients 2025, 17(19), 3027; https://doi.org/10.3390/nu17193027 (registering DOI) - 23 Sep 2025
Abstract
Objectives: Postbiotics have been shown to significantly attenuate atherosclerosis development. This study aimed to elucidate the mechanisms underlying this protective effect, focusing on gut microbiota remodeling, reduction of trimethylamine N-oxide (TMAO), and suppression of the TMAO-activated inflammatory pathway. Methods: A high-fat diet [...] Read more.
Objectives: Postbiotics have been shown to significantly attenuate atherosclerosis development. This study aimed to elucidate the mechanisms underlying this protective effect, focusing on gut microbiota remodeling, reduction of trimethylamine N-oxide (TMAO), and suppression of the TMAO-activated inflammatory pathway. Methods: A high-fat diet (HFD) combined with choline was used to establish an atherosclerosis mouse model. Mice were divided into four groups: control, model, JA845, and Post-JA845 groups. Histological analysis, immunofluorescence staining, inflammatory cytokine detection, 16S rRNA sequencing, metabolomics, and proteomics were used to evaluate the regulatory effects of JA845 postbiotics on gut microbiota composition, TMAO metabolism, and the JAK/STAT3 signaling pathway. Results: Histopathological examination revealed that JA845 postbiotics markedly attenuated atherosclerotic plaque formation in the aorta and improved overall vascular pathology. The treatment effectively regulated lipid metabolism, demonstrating significant reductions in atherogenic LDL and total cholesterol levels, while promoting beneficial HDL elevation. JA845 postbiotics demonstrated potent anti-inflammatory effects by significantly lowering circulating levels of IL-6, IL-33, IL-1β, and TNF-α. Gut microbiota analysis showed substantial compositional changes, with increased abundance of beneficial Bacteroides and Parabacteroides alongside decreased pro-atherogenic Ruminococcus and Akkermansia. At the molecular level, the postbiotics inhibited TMAO generation, suppressed JAK/STAT3 signaling pathway activation, and enhanced endothelial function through upregulated eNOS-mediated nitric oxide production. These coordinated effects collectively contribute to the observed cardiovascular protection. Conclusions: JA845 postbiotics exhibit superior efficacy in reducing TMAO levels, modulating gut microbiota, alleviating inflammation, and improving vascular function, offering a novel strategy for atherosclerosis prevention and treatment. Full article
(This article belongs to the Section Prebiotics and Probiotics)
Show Figures

Figure 1

Previous Issue
Back to TopTop